Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Diphtheria
Human papillomavirus (HPV)
SAGE documentation
Evidence to recommendation table
Clear all
Type of publications
SAGE documentation
(6)
Topics
Evidence to recommendation table
(6)
Regions
Countries
Diseases
COVID-19
(2)
Diphtheria
(1)
Human papillomavirus (HPV)
(3)
Dengue
(2)
Hepatitis B
(2)
Influenza
(1)
Malaria
(2)
Measles
(2)
Mpox // Monkeypox
(1)
Pertussis
(1)
Pneumococcal disease
(2)
Rabies
(2)
Rubella
(2)
Typhoid
(1)
Publication date
2022
(1)
2021
(1)
2017
(4)
Target population
Available to download in languages
English (EN)
(6)
6 results found
2022
∙
SAGE
Annexes to the interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19
2021
∙
SAGE
Annexes to the interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19
2017
∙
SAGE
Diphtheria evidence to recommendation table
2017
∙
SAGE
In 9 to 15-year old females, is 9-valent human papillomavirus vaccine (HPV) vaccine superior to 4-valent or 2-valent HPV vaccines?
2017
∙
SAGE
What is the incremental effectiveness and cost-effectiveness of vaccinating multiple age cohorts versus a single age cohort in high income countries (HIC) and low and middle income countries (LMIC)?
2017
∙
SAGE
What is the public health impact on cervical cancer of administering HPV vaccine to 9 to 15-year old females and males versus to 9 to 15-year old females?
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register